No Data
No Data
Earnings Beat: Stoke Therapeutics, Inc. (NASDAQ:STOK) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts
Don't Ignore The Insider Selling In Stoke Therapeutics
Stoke Therapeutics Advances With Strong Financial Position
Stoke Therapeutics Executives Make Major Moves in Stock Sales!
Insider Sale: CHIEF MEDICAL OFFICER of $STOK Sells 3,884 Shares
Chardan Capital Maintains Stoke Therapeutics(STOK.US) With Buy Rating, Maintains Target Price $24